Canada markets closed
  • S&P/TSX

    20,490.36
    -111.74 (-0.54%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.44 (-0.48%)
     
  • CAD/USD

    0.7832
    -0.0054 (-0.69%)
     
  • CRUDE OIL

    71.96
    -0.65 (-0.90%)
     
  • BTC-CAD

    61,149.12
    +813.55 (+1.35%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • GOLD FUTURES

    1,753.90
    -2.80 (-0.16%)
     
  • RUSSELL 2000

    2,236.87
    +3.96 (+0.18%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • NASDAQ

    15,043.97
    -137.96 (-0.91%)
     
  • VOLATILITY

    20.81
    +2.12 (+11.34%)
     
  • FTSE

    6,963.64
    -63.84 (-0.91%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • CAD/EUR

    0.6677
    -0.0021 (-0.31%)
     

Moderna in talks with FDA to expand COVID-19 vaccine pediatric study

·1 min read
FILE PHOTO: Picture illustration of vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels

(Reuters) -Moderna Inc is in talks with U.S. regulators to expand the size of an ongoing trial testing its COVID-19 vaccines in children aged between five and 11, the drugmaker said on Monday. 

  The objective of the discussion with the U.S. Food and Drug Administration is to enroll a larger safety database, which increases the likelihood of detecting rarer events, the company said. 

  Moderna expects to have a package that supports authorization in winter of 2021 or early 2022, a company spokesperson told Reuters. 

  Earlier in the day, the New York Times reported the U.S. regulators have asked Pfizer Inc-BioNTech and Moderna to expand the size of the trial. 

  They claimed the strength of the studies was inadequate to detect the rare side effects, including myocarditis, an inflammation of the heart muscle and pericarditis, an inflammation of the lining around the heart, the report said.(https://nyti.ms/3xgzuWZ) 

  Pfizer said it has not provided any updates to its previously stated timelines. It had previously said it expects to have data for children aged between 5 and 11 in September. 

  The health regulator has asked the companies to include 3,000 children in their trials, almost double the original number of study participants, the NYT report said, citing people familiar with the matter. 

  FDA did not immediately respond to Reuters request for comment. 

  (Reporting by Mrinalika Roy in Benagluru and Michael Erman in New Jersey; Editing by Shinjini Ganguli) 

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting